There are many challenges in selecting biologic therapies for patients with inflammatory bowel disease. touchIMMUNOLOGY were delighted to speak with Dr. Christopher V. Almario (Cedars Sinai Medical Center, Los Angeles, CA, USA) around his presentation discussing the clinical trial assessing the IBD&Me decision making tool.
The abstract ‘IMPACT OF AN INTERACTIVE IBD BIOLOGICS DECISION AID ON PATIENT OUTCOMES: RESULTS FROM A MULTICENTER RANDOMIZED CONTROLLED TRIAL.’ (Abstract number: 982) was presented at Digestive Disease Week 2022, May 21-24, 2022.
Questions
- What are the challenges in selecting biologic therapies for patients with inflammatory bowel disease? (0:12)
- Could you give us a brief overview of the IBD&Me decision making tool? (0:54)
- Could you tell us a little about the clinical trial assessing this tool, and its findings? (2:31)
- What do you think were the reasons for the lack of difference between the study arms? (5:15)
- What should be the focus of future studies? (6:54)
Disclosures: Christopher Almario discloses consulting for Arena Pharmaceuticals and receiving grant/ research support from the Crohn’s & Colitis Foundation.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of DDW 2022.
